Publications by authors named "Mavis Nye"

Claim this Profile
C
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Dean A Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Mavis Nye

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
Dean Fennell, Daniel Griffiths, Zina Eminton, Abigail Morgan-Fox, Kayleigh Hill, Mavis Nye

BMJ Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
Dean A Fennell, Gareth Griffiths, Christian Ottensmeier, Gerard G Hanna, Sarah Danson, Mavis Nye

Lancet Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Dean A Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G Hanna, Mavis Nye

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
Dean A Fennell, Emma Kirkpatrick, Kelly Cozens, Mavis Nye, Jason Lester

Trials· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis